Nuvalent (NUVL) Net Income towards Common Stockholders (2020 - 2026)

Nuvalent (NUVL) posted Net Income towards Common Stockholders of -$109.3 million for Q1 2026, down 277.94% on a QoQ basis from -$28.9 million in Q4 2025, and down 29.2% year-over-year from -$154.3 million in Q1 2025.

Nuvalent (NUVL) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Nuvalent's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$109.3 million for Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 29.2% year-over-year to -$109.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$360.3 million (down 19.75% YoY) and the FY2025 annual result came in at -$335.6 million, down 28.7% from the prior year.
  • Net Income towards Common Stockholders was -$109.3 million for Q1 2026 at Nuvalent, down from -$28.9 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$18.6 million in Q1 2022 and bottomed at -$122.4 million in Q3 2025.
  • A 5-year average of -$54.0 million and a median of -$38.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 201.38% — and 2025, when it soared 61.33%.
  • Nuvalent's Net Income towards Common Stockholders stood at -$27.5 million in 2022, then tumbled by 39.44% to -$38.3 million in 2023, then tumbled by 95.24% to -$74.8 million in 2024, then surged by 61.33% to -$28.9 million in 2025, then plunged by 277.94% to -$109.3 million in 2026.
  • Business Quant data shows NUVL's Net Income towards Common Stockholders at -$109.3 million in Q1 2026, -$28.9 million in Q4 2025, and -$122.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -625.73
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -0.68
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 366.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -453.82 Mn
10 Nuvalent 9.75 Bn 9.75 Bn - -109.28 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -109.28 Mn
Dec 31, 2025 -28.91 Mn
Sep 30, 2025 -122.44 Mn
Jun 30, 2025 -99.65 Mn
Mar 31, 2025 -84.58 Mn
Dec 31, 2024 -74.76 Mn
Sep 30, 2024 -84.35 Mn
Jun 30, 2024 -57.17 Mn
Mar 31, 2024 -44.48 Mn
Dec 31, 2023 -38.29 Mn
Sep 30, 2023 -33.65 Mn
Jun 30, 2023 -29.09 Mn
Mar 31, 2023 -25.19 Mn
Dec 31, 2022 -27.46 Mn
Sep 30, 2022 -20.58 Mn
Jun 30, 2022 -19.60 Mn
Mar 31, 2022 -18.57 Mn
Dec 31, 2021 -40.78 Mn
Sep 30, 2021 -12.43 Mn
Jun 30, 2021 -9.85 Mn